More men with breast cancer are opting for double mastectomy

Thursday, September 03, 2015

The number of men with invasive cancer in one breast who undergo surgery to remove both breasts is on the rise, according to a new report published in JAMA Surgery.

The report, written by researchers from the American Cancer Society and the Dana-Farber Cancer Institute, is the first to establish this trend, which mirrors a rise in the amount of U.S women also having the surgery for unilateral breast cancer over the last 20 years. However, researchers say there is a lack of evidence to support any survival benefit as a result of having both the affected and unaffected breasts removed.

Previous studies have shown a significant increase in the number of contralateral prophylactic mastectomy (CPM) procedures to remove both breasts in cases where women have invasive cancer in one breast. In 1998, about 2.2% of these women underwent the surgery, but this figure rose to 11% in 2011. However, it is unknown whether the use of CPM to treat male breast cancer, which accounts for around 1% of all breast cancer cases, is also increasing.

To explore whether this is the case, Jemal and colleagues looked into the treatment received by 6,332 men who underwent surgery for unilateral invasive breast cancer between 2004 and 2011. The team used nationwide data from the North American Association of Central Cancer Registries to examine the temporal trends in and factors associated with the use of CPM among the study population.

The results showed that the rates of CPM almost doubled between 2004 and 2011, from 3.0% to 5.6%. Further analysis showed that the sociodemographic factors associated with the increase were being white, younger age and having private insurance – the same factors that are linked to an increased use of CPM among women.

Who We Are

Biocell Ultravital™ researches and develops innovative, 100% natural, pharmaceutical-grade bioproducts, on an exclusive basis worldwide. These products optimise cell nutrition and energy, producing a preventative and curative action which, in addition to treating pre-symptoms and symptoms by means of cell renewal, refuels and corrects the cell structure of tissues and organs, preventing the appearance of the functional stress loads which give rise to poor cell formation, degenerative diseases, and their after-effects.


Product developed under pharmaceutical control according to European CE standards. Made in the EC by Biocell Laboratory France, licensed and authorized by Biocell Ultravital GmbH, Switzerland.


This website is governed by applicable laws and government regulations. Please see our Privacy Policy.
Use of this site constitutes your consent to application of such laws and regulations.

© 2021 Biocell Ultravital